- New agreement extends usage of SRS to commercial organizations worldwide and establishes joint research efforts in bioinformatics
Cambridge, MA, USA, Heidelberg, Germany, March 17, 2004 – LION bioscience (Nasdaq: LEON) and the EMBL-European Bioinformatics Institute (EBI) today announced an expansion of their relationship, which will benefit the bioinformatics community worldwide. As part of the new agreement, LION has agreed to allow the EBI, as well as other academic institutions, to use the latest versions of SRS to provide their research critical content to researchers worldwide – at both academic institutions and commercial organizations – with no restrictions. The SRS server at EBI will be set up to be the public reference server worldwide. In addition, the organizations have agreed to work more closely together on developing new technologies in the field of bioinformatics. Specifically this will be to extend the scope of EBI resources made available through the SRS interface and a collaboration on the development of visualization components to enable fast and intuitive comprehension of complex scientific data.
“We believe this collaboration will further strengthen LION as a key provider of critical bioinformatics technology and allow us to explore new areas of collaboration and product development with key research institutions worldwide,” said Thure Etzold, President of LION bioscience Ltd., UK.
Graham Cameron, Associate Director of the EBI, added, “LION is an important partner to the EBI and to the world’s leading academic institutions, pharmaceutical, and biotechnology companies. We look forward to continuing to work closely with them”.
For further information please contact:
+49 (0) 6221 4038 158
European Bioinformatics Institute:
+44 (0) 1223 494467
SRS is the industry leading software program to provide fast access to diverse life science data - genetic, protein, cellular, molecular and clinical - from public and proprietary sources, regardless of data format. SRS is used today by more than 27,000 users in more than 300 commercial and academic organizations around the globe. SRS provides global bioinformatics platforms for pharmaceutical companies such as Eli Lilly, Johnson&Johnson and AstraZeneca, as well as forming the basis of genomics portals for data providers such as Celera, Incyte, Derwent and Affymetrix.
About European Bioinformatics Institute
The European Bioinformatics Institute (EBI) is a non-profit academic organization that forms part of the European Molecular Biology Laboratory (EMBL). The EBI is a center of research and services for bioinformatics that aims to ensure that the growing body of information from molecular biology and genome research is placed in the public domain and is freely accessible to the entire scientific community. For more information, please visit www.ebi.ac.uk.
About LION bioscience
LION bioscience (ISIN: DE0005043509, Reuters: LIOG, Bloomberg: LIO, Nasdaq: LEON) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. Since it was founded in 1997, the company has become a recognized leader in the area of life sciences informatics. LION has operations worldwide with its headquarter in Heidelberg, Germany, and offices in Cambridge, UK, Cambridge, MA, and San Diego, CA, USA. LION’s products are distributed by CTC Systems in Japan and DigiGenomics in Taiwan and Korea.
LION’s (https://www.netgenics.com) solutions are used by more than 27,000 researchers at 300 academic and industrial customers globally. LION’s offerings include SRS for bioinformatics data access, LION Target Engine™ for target identification and validation, LION Lead Engine™ for lead identification and optimization, iDEA pkEXPRESSä with analysis and prediction tools for ADME, and LION SolutionCenter™ professional services.
Except for the historical information contained herein, the matters set forth in this press release are forward looking within the meaning of the Private Securities Litigation Reform Act of 1995, and other applicable U.S. and German laws. These forward-looking statements may include projections, assumptions, estimates, targets, and descriptions of future events. Such statements are based on currently available information and on LION’s current expectations as to future events that may not prove to be accurate. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Many factors could cause the actual results, performance or achievements of LION to be materially different from those that may be projected, expected, targeted, expressed or implied by such statements. All roll-out plans and future dates with respect to completion of development and market release of LION products are target dates only based on the company’s current planning and may change in the future. Any delays in the current product release schedule will have a materially adverse effect on the company’s targets for fiscal year. We refer you to LION’s Annual Reports on Form 20-F, as filed with the Securities and Exchange Commission (SEC), as filed on September 30, 2003, in which these and other risk factors are discussed. In the event of any material conflicts between the two documents, Form 20-F should be relied on. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained in this announcement, whether as a result of new information, change of assumptions or business model, future developments or otherwise.
| || |